A yeast-based product (EpiCor®, a dried Saccharomyces cerevisiae fermentate) was compared to placebo to determine effects on the incidence and duration of cold and flu-like symptoms in healthy subjects recently vaccinated for seasonal influenza.
In a 12-week, randomized, double-blind, placebo-controlled clinical trial, 116 participants received daily supplementation with 500 mg of EpiCor or placebo for 12 weeks.
Data collected included periodic in-clinic examinations and serologic evaluations at baseline, 6- and 12-weeks.
Subjects also utilized a standardized self-report symptom diary during the study. Participants receiving the yeast-based product had significantly fewer symptoms and significantly shorter duration of symptoms when compared with subjects taking a placebo.
[Note: For more detail on the results of this study, see a related news release.]
*Source: Urologic Nursing. February 2008, vol. 28, no. 1, pp. 50-55. Moyad, MA, Robinson LE, Zawada JM, Kittelsrud JM, Chen DG, Reeves SG, Weaver SE. University of Michigan, Ann Arbor, Michigan, USA.